Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Baxter
Johnson and Johnson
Colorcon
Harvard Business School

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 9,567,578

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,567,578
Title:Cell line containing a knockout of the glutamine synthetase (GS) gene and a method of producing target proteins using a GS knockout HEK293 cell line
Abstract: The present invention relates to a novel GS (glutamine synthetase) gene knock out transgenic HEK293 (human embryonic kidney 293) cell line and a production method of a target protein using the said transgenic HEK293 cell line. Particularly, the present inventors eliminated the expression of GS in the HEK293 cells in order to overcome a barrier of the cell line selection caused by the over-expression of GS, for producing a target protein by GS/MSX system, by which the efficiency of the cell line selection for the high production of a target protein would be increased and accordingly the protein production by the selected cell line would be increased, suggesting that the human originated transgenic HEK293 cell line could be efficiently used for the production of a target protein.
Inventor(s): Lee; Gyun-Min (Daejeon, KR), Yu; Da Young (Daejeon, KR), Noh; Soo Min (Daejeon, KR)
Assignee: Korea Advanced Institute of Science and Technology (Daejeon, KR)
Application Number:15/138,165
Patent Claims:see list of patent claims

Details for Patent 9,567,578

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Nps Pharmaceuticals, Inc. NATPARA parathyroid hormone For Injection 125511 2015-01-23 ⤷  Try it Free 2036-01-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
AstraZeneca
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.